The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure (Q-SYMBIO trial)

Key finding

2-year double-blind multi-center RCT (n=420) in chronic heart failure found 300mg/day CoQ10 (ubiquinone) reduced cardiovascular mortality by 43% and major adverse cardiac events by 50% vs placebo.

Critique

Q-SYMBIO is among the stronger supplement trials in the literature. Multi-center, double-blind, placebo-controlled, 2-year duration, and a hard clinical endpoint (cardiovascular mortality). The 43% mortality reduction represents a clinically meaningful effect size, not just statistical significance. The key interpretive nuance is that enrolled patients were already receiving optimal guideline-directed heart failure therapy, so the benefit represents an additive effect on top of standard care — applicable to a specific clinical context rather than general prevention in healthy adults.

What would be more convincing

Given the strength of this trial, what's missing is independent large-scale replication. A second 1,000+ patient multi-center RCT conducted in a different healthcare system would move CoQ10 in heart failure from 'likely beneficial' to 'guideline-recommended.' Smaller supporting trials exist but a definitive replication would close the case.

Reviewed 2026-04-21 · Opinion based on verifiable facts in the published paper.